May 23, 2013
On May 10, Mallinckrodt, the Pharmaceutical business of Covidien, released a customer letter regarding the unplanned HFR shutdown that began in November 2012. NRG, operator of the High Flux Reactor (HFR), recently reported they continue to make progress in completing the necessary repairs to the reactor. However, they also announced that they do not anticipate the HFR will return to service before early June.
Mallinckrodt has assessed the molybdenum-99 (Mo-99) options available and currently expect to meet customer needs for technetium-99m (Tc-99m) generators in May and June provided current projections of reactor availability hold true.
Please find letters from Mallinckrodt and NRG below.